Pfizer to Test Second Paxlovid Course in Patients With Covid Rebound

Shown to reduce rates of hospitalization and death, a five-day course of Paxlovid has become the go-to treatment for high-risk people with Covid-19, far outperforming rival Merck & Co.’s molnupiravir. Since the spring, however, numerous patients have reported resurgences in either viral infection or symptoms, or both, after their initial course.


Leave a Comment

%d bloggers like this: